CHARLOTTESVILLE, Va., May 16, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals announced today that its Chairman, Bankole A. Johnson, D.Sc., M.D., was selected by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a unit of the National Institutes of Health (NIH), to deliver the 5th Annual Jack Mendelson Honorary Lecture on Tuesday, May 21, 2013. The Jack Mendelson Honorary Lecture Series was established as a tribute to Dr. Jack Mendelson, who has made remarkable scientific contributions to the field of clinical alcohol research. The purpose of the Lecture Series is to highlight clinical/human research in the alcohol field by an investigator who has made significant and long-term contributions to the understanding of alcoholism susceptibility, the effects of alcohol on the brain and other organs, and the prevention and treatment of alcohol use disorders. The title of Dr. Johnson's lecture is "Personalizing the Treatment of Alcoholism" and the lecture will be held at the Lipsett Amphitheater on the NIH campus.
Additional information about the Jack Mendelson Honorary Lecture Series can be found at the following link:
About Dr. Bankole Johnson
Professor Bankole Johnson is a world-famous pioneer in the development of medications for the treatment of alcohol abuse. He currently serves as the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia and as a Professor in the Department of Neuroscience and the Department of Medicine. Additionally, he is the Principal Investigator on several NIH-funded research studies. A practicing physician, psychiatrist and researcher for more than 25 years, Dr. Johnson has transformed our understanding of how abnormalities in the brain can promote addiction. These investigations also led him to discover drugs effective at alleviating alcohol addiction.
About ADial Pharmaceuticals, LLC
ADial Pharmaceuticals is a privately held pharmaceutical company developing medications for treating addiction diseases and disorders, including alcohol and drug addictions (cocaine, opioids, methamphetamines), as well as other addiction-like behaviors such as those related to obesity and eating disorders. The company's most advanced compound, AD04, specifically targets alcohol use disorder (previously called alcohol abuse and dependence) in patients with selected genotypes. For more information about ADial Pharmaceuticals, please visit http://www.adialpharma.com.
CONTACT: William Stilley, CEO (434) 422-9800 ext. 103 email@example.com
Source:ADial Pharmaceuticals, LLC